netFormulary NHS
North Staffordshire Joint Formulary
North Staffordshire Clinical Commissioning Group
Stoke-on-Trent Clinical Commissioning Group
 Introduction

Preferred Prescribing list for North Staffordshire CCGs, including University Hospitals of North Midlands NHS Trust, Midlands Partnership NHS Foundation Trust and North Staffordshire Combined Healthcare NHS Trust

Useful Links

ESCAs Guidelines and Clinical Pathways Patient Group Directions
Formulary Documentation High Cost Drugs Information Drug Discontinuations & Shortages
Area Prescribing Committee Documents New Medicines Committee Documents Monthly Newsletters
Self Care and Over the Counter Medicines Prescribing Decline To Prescribe Form  Care Home Prescribing Resourses
Covid 19 - Interim Clinical Information    

 CCG Formularies

South Staffordshire Joint Formulary  Central & Eastern Cheshire Formulary  Birmingham & Surrounds Formulary

Clinical Formularies

Woundcare Formulary Continence Prescribing Formulary Antimicrobial Guidelines
How to guide for North Staffordshire Joint Formulary  

 

News Feed

07/05/2020 - New Covid-19 information link

The North Staffordshire Joint Formulary has a new COVID 19 link titled Interim Clinical Information. Please use this link to access local and national documents recommending advice and guidance during this time. If you have any queries relating to this please use the Feedback tab on the formulary front page.

Medicines Information Team


19/03/20 Esmya: Urgent patient level recall

Gedeon Richter (UK) Ltd is recalling all unexpired stock of Ulipristal acetate (Esmya) from patients, pharmacies and wholesalers following a new case of liver failure requiring liver transplant in a patient taking the medicine. To protect patients while a safety review is conducted, the European Medicines Agency's safety committee, Pharmacovigilance Risk Assessment Committee, (PRAC) has recommended that women stop taking 5mg ulipristal acetate (Esmya and generic medicines) for uterine fibroids.

Clinicians must contact patients who have been supplied Esmya and ask them to stop taking their medication as soon as possible and return any unused medicine to their pharmacy. All patients currently being treated with Esmya/ulipristal acetate for uterine fibroids should be provided advice about other possible treatments for uterine fibroids.  


24/02/20: Three Insuman preparations to be discontinued.

Three presentations of Insuman Basal and Insuman Comb are to be discontinued owing to limited capacity at the manufacturing site. The manufacturer says the discontinuations are not due to any safety issue.

The presentations being discontinued are:

  • Insuman Comb 15 100IU/mL suspension for injection in a cartridge (expected end of supply June 2020). This is the only presentation of Insuman Comb 15.
  • Insuman Basal 100IU/mL suspension for injection in a vial (expected end of supply May 2020).
  • Insuman Comb 25 100IU/mL suspension for injection in a vial (expected end of supply June 2020).

No new patients should be started on these presentations, and existing patients should be switched to a suitable alternative. See individual entries on the formulary for alternatives.

 


24/12/19: Antimicrobial guidelines for Staffordshire and Stoke CCGs

The Staffordshire and SOT Antimicrobial prescribing guidelines for managing common infections in primary care have been updated. This document is now available on netFormulary. Clinicians should familiarise themselves with the document and employ its use in clinical practice. Any queries can be directed to the Medicines Optimisation Team.


21/11/19: Asthma guidelines for Staffordshire and SOT CCGs

The APC/APG has approved the Staffordshire and SOT CCGs Asthma Guidelines. This document is now available on netFormulary. Clinicians should familiarise themselves with the document and employ its use in clinical practice. Any queries can be directed to the Medicines Optimisation Team. 


14/11/19: Updated Renal ESCAs in North Staffs (approved by APC)

Clinicians should take note of the updated ESCAs for Lanthanum and Sevelamer, both used for the treatment of hyperphosphatemia in pre-dialysis CKD patients in North Staffordshire. Any questions relating to these documents can be sent to the Medicines Optimisation team.


>>> more news

 

 


NetFormulary
   Visits = 42954
   Last updated: 06/07/2020 08:09:46..